Understanding the Regulatory Submission Process: A Look at…

What is an NDA/BLA?

An NDA (New Drug Application) or BLA (Biologics License Application) is a document submitted by pharmaceutical companies to regulatory agencies like the FDA and EMA. It contains all the information necessary for these organizations to evaluate whether a new drug or biologic should be approved for sale in their respective regions.

The NDA/BLA includes data from clinical trials, manufacturing processes, pharmacology studies, and other relevant information that demonstrates the safety, efficacy, and quality of the product.

The Review Process

Once an NDA or BLA is submitted, it enters a queue where it is assigned to reviewers. These experts from the FDA or EMA evaluate the application based on specific criteria such as drug safety and efficacy.

During this process, the agency may request additional data (RTF - Request for Technical Information) if more information is needed to make an informed decision.

live demo · related simulation● LIVE

Timeline and Accelerated Approvals

The review timeline can vary significantly depending on the complexity of the application and the need for additional data. For certain drugs that address serious or life-threatening conditions, the FDA offers Fast Track and Breakthrough Therapy designations to expedite the review process.

These designations allow for more frequent interactions between the company and the regulatory agency, as well as potential priority review, which can reduce the typical 10-month review period to just six months.

Why It Matters

The regulatory submission process is crucial because it ensures that only safe and effective drugs are approved for public use. This process helps protect patients from harmful side effects and guarantees that new treatments meet high standards of quality.

Understanding this process also aids pharmaceutical companies in planning their drug development strategies, ensuring they have the necessary data to support a successful application.

Frequently asked questions

What happens if additional data is requested during the review?

If the FDA or EMA requests additional data (RTF), the company must provide this information within a specified timeframe. This can delay the approval process, but it ensures that all necessary safety and efficacy data are thoroughly reviewed.

Can any drug be submitted as an NDA/BLA?

No, only drugs that have completed extensive clinical trials and meet strict criteria for safety and efficacy can be submitted as an NDA or BLA. These applications are rigorously evaluated to ensure they provide significant benefits to patients.

How long does the entire process usually take?

The total time from submission to approval can range widely, but it typically takes several years due to the extensive review and potential need for additional data. Fast Track or Breakthrough Therapy designations may help shorten this timeline.

What are the benefits of getting a drug approved through these pathways?

Getting a drug approved through Fast Track or Breakthrough Therapy can lead to faster access for patients, increased funding opportunities, and reduced development costs. These designations also facilitate more frequent communication between the company and regulatory agencies.

Try it live

Everything above runs in your browser — open Regulatory Submission Simulator (FDA/EMA) and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open Regulatory Submission Simulator (FDA/EMA) simulation

Understanding the Regulatory Submission Process: A Look at NDA/BLA Reviews